Fingolimod Hydrochloride, also known as FTY720-HCl or Gilenya, is a medication used to treat multiple sclerosis (MS). It was developed by Novartis and approved by the US Food and Drug Administration (FDA) in 2010 for the treatment of relapsing-remitting MS.
The chemical name of Fingolimod Hydrochloride is (S)-2-amino-2-(2-[4-octylphenyl]ethyl)propane-1,3-diol hydrochloride.
The molecular formula of Fingolimod Hydrochloride is C19H34ClNO2.
The formula weight of Fingolimod Hydrochloride is 343.92 g/mol.
The CAS number of Fingolimod Hydrochloride is 162359-56-0.
Top ten keywords from Google and synonyms:
- Gilenya side effects
- Fingolimod mechanism of action
- Fingolimod clinical trials
- Fingolimod dosage
- FTY720-HCl pharmacokinetics
- Multiple sclerosis treatment
- Neurological disorders
- Immune-modulating therapy
- FTY720-HCl safety
- Gilenya benefits
Synonyms: FTY720-HCl, Gilenya, (S)-2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride
Health benefits of Fingolimod Hydrochloride:
Fingolimod Hydrochloride has been primarily used for the treatment of multiple sclerosis (MS). Specifically, it is used to reduce the frequency of relapses and slow down the progression of disability associated with MS. Moreover, it may help to decrease inflammation and prevent damage to neurons in the brain and spinal cord.
Fingolimod Hydrochloride works by modulating the activity of immune cells that contribute to the development and progression of MS. By binding to specific receptors on immune cells, Fingolimod Hydrochloride prevents them from leaving lymph nodes and entering the bloodstream. As a result, these immune cells are unable to reach the brain and spinal cord, where they would otherwise attack and damage nerve cells. This immune-modulating effect of Fingolimod Hydrochloride can help to reduce the frequency and severity of MS relapses and slow down the progression of disability.
Fingolimod Hydrochloride is a sphingosine-1-phosphate receptor modulator that binds to specific receptors on immune cells called sphingosine-1-phosphate (S1P) receptors. By binding to these receptors, Fingolimod Hydrochloride blocks the ability of immune cells to exit from lymph nodes and enter the bloodstream. As a result, fewer immune cells are able to reach the central nervous system, which helps to prevent inflammation and neurodegeneration in MS patients.
Like any medication, Fingolimod Hydrochloride may have some potential side effects. However, most reported side effects of Fingolimod Hydrochloride are mild to moderate in severity and manageable. Common side effects include headache, fatigue, diarrhea, back pain, and cough. In rare cases, severe adverse reactions such as liver damage, heart problems, and infections may occur. Therefore, it is important to discuss the risks and benefits of Fingolimod Hydrochloride with your doctor before taking it.
The recommended dosage of Fingolimod Hydrochloride for the treatment of MS is 0.5 mg once daily. The medication should be taken orally with or without food. Patients should be monitored for at least six hours after the first dose of Fingolimod Hydrochloride to ensure that their heart rate and blood pressure remain stable. If a dose is missed, patients should take the next scheduled dose at the regular time. Patients should not take a double dose of Fingolimod Hydrochloride to make up for the missed dose.
In conclusion, Fingolimod Hydrochloride is an effective treatment for multiple sclerosis that works by modulating the activity of immune cells. It helps to reduce the frequency of relapses and slow down the progression of disability associated with MS. Although Fingolimod Hydrochloride has shown potential benefits in clinical trials, more studies are needed to establish its long-term safety and efficacy. Therefore, patients should always consult with their healthcare provider before starting any new medication